Out of Heartache, Hope Surfaces for Colton’s Metabolic Disorder
Before his first breath, Colton Iverson had already received the gift of a lifetime. Just days old, he became the youngest patient to go on a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of a life-threatening genetic condition called very long-chain acyl-CoA dehydrogenase, or VLCAD, deficiency.
For his parents, the hope it inspired did not come without heartache.
“Colton wouldn’t be here today without our first born, his older sister Cody,” said his mom, Lisa Iverson.
Original Article Source Credits: Seattle Children's , https://pulse.seattlechildrens.org/
Article Written By: LINDSAY KURS
Original Article Posted on: NOVEMBER 20, 2020
Link to Original Article: https://pulse.seattlechildrens.org/hope-surfaces-for-rare-metabolic-disorder-vlcad/